NORGESIC FORTE
LOE ApproachingNDAORALTABLET
Approved
Mar 1964
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
NORGESIC FORTE by Bausch + Lomb is clinical pharmacology orphenadrine citrate is a centrally acting (brain stem) compound which in animals selectively blocks facilitatory functions of the reticular formulation. First approved in 1964.
Drug data last refreshed 4h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NORGESIC FORTE is an oral tablet combining orphenadrine citrate, aspirin, and caffeine for the treatment of musculoskeletal pain and discomfort. Orphenadrine is a centrally acting muscle relaxant that blocks facilitatory functions in the reticular formation of the brain stem, while aspirin and caffeine provide analgesic and adjunctive benefits. The precise therapeutic mechanism remains incompletely understood but is believed to involve analgesic and anticholinergic properties.
$0.004BPart D
LOE ApproachingDeclining
Declining commercial trajectory with minimal Part D claims signals a mature, legacy product with shrinking team and budget allocation.
Mechanism of Action
CLINICAL PHARMACOLOGY Orphenadrine citrate is a centrally acting (brain stem) compound which in animals selectively blocks facilitatory functions of the reticular formulation. Orphenadrine does not produce myoneural block, nor does it affect crossed extensor reflexes. Orphenadrine prevents…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
With zero linked job openings and LOE approaching, NORGESIC FORTE offers limited career growth opportunity; roles are primarily sales and brand maintenance focused on managing decline in a competitive market. This product is suited for professionals seeking stability in a legacy portfolio rather than launch-phase innovation and growth.
Worked on NORGESIC FORTE at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.